Sandoz Launches First Generic of Esbriet.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article reports that Sandoz, a global leader in generic and biosimilar medicines, today announced the U.S. launch of its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech's Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). It mentions that Sandoz developed the medicine in-house and continue to build our expertise and infrastructure to support our long-term commitment to grow our respiratory portfolio.